Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTreatt Regulatory News (TET)

Share Price Information for Treatt (TET)

Share Price is delayed by 15 minutes
Get Live Data
301.50    -0.50 (-0.17%)
Bid:
302.00
Ask:
302.50
Spread: 0.50 (0.166%)
Market Cap: £177.99m
TET Live PriceLast checked at - London Stock Exchange

Intraday Treatt Share Chart

Trading Update

24 Jul 2025 07:00

RNS Number : 3971S
Treatt PLC
24 July 2025
 

TREATT PLC

("Treatt" or "the Group")

Trading Update

Treatt, the manufacturer and supplier of a diverse and sustainable portfolio of natural extracts and ingredients for the beverage, flavour and fragrance industries, provides an update on trading for the financial year ending 30 September 2025 ("FY 2025").

Treatt has continued to face trading headwinds since the announcement of the interim results on 13 May 2025 which will affect the performance for the full year. As a result, we now expect revenue of between £130m and £135m and profit before tax and exceptionals (PBTE) of between £9m and £11m, lower than previous guidance1.

This revised outlook has been principally driven by the following incremental factors:

·  A reduction in second half sales, with revenue now expected to be £66m, compared with previous guidance of £82m. While we have successfully converted several pipeline opportunities, including encouraging wins with new customers in Premium, this conversion has been slower than anticipated.

 

· Lower repeat customer volumes, driven by competitive pressures and North American consumer confidence.

 

· The weaker US dollar exchange rate has resulted in a c£0.5m profit headwind as a result of translation of USD profits.

 

In the interim results, we drew attention to ongoing market dynamics affecting the outlook for the year, both of which have continued:

· Lower demand in Heritage from sustained high citrus oil prices affecting buying patterns, and leading to reformulation. Although citrus oil prices have started to reduce more recently, this has continued to impact both short-term buying patterns in value added citrus products and citrus margins. We expect a reduction of this adverse impact as citrus oil pricing normalises.

 

· Consumer confidence in the US, combined with geopolitical and tariff uncertainty in the US was impacting the overall beverage market in North America. This has persisted, reflected in extended softening of demand.

 

To mitigate inflationary cost pressures and maintain our investment in growth areas, we implemented several self-help measures in the first half which are continuing, with a focus on simplification and efficiency gains. We do not anticipate any significant increase in administrative expenses in FY 2025 compared to FY 2024.

The £5m share buyback was completed in May 2025. The balance sheet remains strong, and we now expect to report a low net debt position at the year-end as a result of the expected lower level of profitability for the period (compared to previous guidance of £1-3m of net cash). 

Treatt continues to execute its strategy, and we remain committed to driving revenue growth through customer centricity, reach expansion and innovation, as demonstrated by the planned opening of our Shanghai innovation centre later this year. We have also strengthened our senior teams to add new skillsets and a focus on new markets and growth opportunities across the Group.

The sales pipeline has strengthened during the year, and we continue to be focused on revenue opportunities and better margins in FY 2026 and beyond.

(Note 1 - Previous guidance at 10 April 2025 was £146-£153m revenue and £16m-£18m PBTE.)

 

Treatt PLC +44 (0) 1284 702500

David Shannon Chief Executive Officer

Ryan Govender Chief Financial Officer

Joint Brokers

Investec Bank Plc +44 (0) 20 7597 5970

Patrick Robb

David Anderson

 

Peel Hunt LLP +44 (0) 20 7418 8900

George Sellar

 

Financial PR

MHP +44 (0) 20 3128 8100

Tim Rowntree Treatt@mhpgroup.com

Eleni Menikou 

 

This announcement contains inside information within the meaning of the Market Abuse Regulation. The person responsible for arranging release of this announcement on behalf of Treatt is Nick Hartigan, General Counsel & Company Secretary.

 

About the Group

Treatt is a global, independent manufacturer and supplier of a diverse and sustainable portfolio of natural extracts and ingredients for the flavour, fragrance and multinational consumer product industries, particularly in the beverage sector. Renowned for its technical expertise and knowledge of ingredients, their origins and market conditions, Treatt is recognised as a leader in its field. The Group employs approximately 350 staff in Europe, North America and Asia and has manufacturing facilities in the UK and US. Its international footprint enables the Group to deliver powerful and integrated solutions for the food, beverage and fragrance industries across the globe. For further information about the Group, visit www.treatt.com.

 

CAUTIONARY STATEMENT ABOUT FORWARD-LOOKING STATEMENTS

This announcement contains forward-looking statements that are subject to risk factors associated with, among other things, the economic and business circumstances occurring from time to time in the countries, sectors and markets in which the Group operates. It is believed that the expectations reflected in these statements are reasonable, but they may be affected by a wide range of variables which could cause actual results to differ materially from those currently anticipated. No assurances can be given that the forward-looking statements in this announcement will be realised. The forward-looking statements reflect the knowledge and information available at the date of preparation of this announcement and the Group undertakes no obligation to update these forward-looking statements. Nothing in this announcement should be construed as a profit forecast.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFIFVSDVISFIE
Date   Source Headline
4th Feb 202511:55 amRNSHolding(s) in Company
30th Jan 20254:17 pmRNSResult of AGM
30th Jan 20257:00 amRNSAGM Trading Update
20th Dec 202411:24 amRNSNotification of Transactions of Directors
17th Dec 20244:07 pmRNSAnnual Report and Notice of Annual General Meeting
17th Dec 20241:44 pmRNSNotification of Transactions of Directors
4th Dec 20241:47 pmRNS2024 Final Dividend
4th Dec 20247:00 amRNSFull Year Results
2nd Dec 20247:00 amRNSBlock Listing Six Monthly Return
2nd Dec 20247:00 amRNSBlock Listing Six Monthly Return
15th Nov 20247:00 amRNSBoard Change
16th Oct 202412:00 pmRNSChange in Director's Duties
10th Oct 20247:00 amRNSTrading Update
24th Sep 20242:06 pmRNSDirector/PDMR Shareholding
20th Aug 202411:06 amRNSNotification of Transactions of Directors
12th Jul 202410:49 amRNSDirector/PDMR Shareholding
4th Jun 202410:35 amRNSBlock Listing Six Monthly Return
4th Jun 202410:25 amRNSBlock Listing Six Monthly Return
3rd Jun 20247:00 amRNSDavid Shannon joins as CEO
14th May 20247:00 amRNSHalf Year Results
30th Apr 20244:02 pmRNSVoting Rights and Capital
10th Apr 20247:00 amRNSHalf Year Trading Update & Notice of Results
19th Mar 20243:40 pmRNSNotification of Transactions of Directors
4th Mar 20247:00 amRNSAppointment of Chief Executive Officer
13th Feb 20249:35 amRNSHolding(s) in Company
31st Jan 20242:41 pmRNSNotification of Transaction of PDMR
25th Jan 20243:49 pmRNSResult of AGM
25th Jan 20247:00 amRNSAGM Trading Update
23rd Jan 20241:57 pmRNSTotal Voting Rights
21st Dec 20232:07 pmRNSNotification of Transaction of Director
15th Dec 20236:09 pmRNSNotification of Transactions - Replacement
15th Dec 20234:42 pmRNSNotification of Transactions of Directors
13th Dec 20237:00 amRNSInterim Chief Financial Officer Appointment
12th Dec 20234:24 pmRNSAnnual Report and Notice of Annual General Meeting
1st Dec 20237:01 amRNSBlock Listing Six Monthly Return
1st Dec 20237:00 amRNSBlock Listing Six Monthly Return
28th Nov 20234:15 pmRNS2023 Final Dividend
28th Nov 20237:00 amRNSFull Year Results
20th Oct 20237:00 amRNSCEO Succession
10th Oct 20237:00 amRNSTrading Update
18th Sep 20234:11 pmRNSHolding(s) in Company
15th Aug 20234:14 pmRNSNotification of Transactions of Directors
28th Jul 202310:43 amRNSTotal Voting Rights
13th Jul 202312:15 pmRNSReplacement - Director/PDMR Shareholding
13th Jul 202311:09 amRNSNotification of Transaction of Director
21st Jun 20234:05 pmRNSNotification of Transactions of Director
12th Jun 20234:13 pmRNSDirector Declaration
7th Jun 20232:28 pmRNSBlock Listing Application
1st Jun 20237:00 amRNSBlock listing Six Monthly Return
19th May 20235:10 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.